Diabetes and Blood Pressure Medication Prescriptions Increase Among Children and Teens
CHICAGO, April 6, 2009--The number of children and teens prescribed medicine to treat high blood pressure or diabetes appears to have increased between 2004 and 2007. Joshua N. Liberman, Ph.D., of CVS Caremark in Hunt Valley, Md., and colleagues analyzed the prescription records of more than 5 million commercially insured individuals ages 6 to 18 covered by a pharmacy benefits manager.
The prevalence of children and teens who were prescribed medications for hypertension (high blood pressure), dyslipidemia (abnormal cholesterol) or diabetes (including insulin) increased 15.2 percent, from 3.3 per 1,000 youths in November 2004 to 3.8 per 1,000 youths in June 2007. "The increasing use of oral anti-diabetic and antihypertensive pharmacotherapy among children and adolescents, especially in the younger age group, indicates either an increased awareness of treatment needs or increased incidence of cardiovascular risk factors typically associated with adult populations," the authors write.
When assessed separately, cholesterol-controlling therapy was uncommon (prescribed to 0.2 per 1,000 youths overall) and declined 22.9 percent during the study period. "The decrease in treatment of dyslipidemia may reflect the ongoing controversy regarding statin use," the authors conclude.
The results indicate that these drugs are not currently being overused in this population, writes Stephen R. Daniels, M.D., Ph.D., of the University of Colorado Denver School of Medicine, in an accompanying editorial. "While the potential for misuse of these medications remains, that does not appear to be happening at this time. Nevertheless, it will be important to collect data in an ongoing manner to monitor use of these medications but also to identify appropriateness of use and ultimate reduction of risk factor levels in children and adolescents."
(Arch Pediatr Adoles Med. 2009;163[4]:357-364, 389-391. Available to the media pre-embargo at www.jamamedia.org. To contact Joshua N. Liberman, Ph.D., call Christine K. Cramer at 401-770-3317 or e-mail ckcramer@cvs.com. To contact Stephen R. Daniels, M.D., Ph.D., call Susan Hotchkiss at 720-777-2766 or e-mail hotchkiss.susan@tchden.org, or call Jim Spencer at 303-724-5377 or e-mail jim.spencer@ucdenver.edu).
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
For more information, contact JAMA/Archives media relations at 312/464-JAMA (5262) or e-mail mediarelations@jama-archives.org.
Pharma Industry News Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
